144 related articles for article (PubMed ID: 2283256)
41. Can gadolinium be safely given in renal failure?
Weissleder R
AJR Am J Roentgenol; 1996 Jul; 167(1):278-9. PubMed ID: 8659405
[No Abstract] [Full Text] [Related]
42. Experimental study of DOTA-gadolinium. Pharmacokinetics and pharmacologic properties.
Allard M; Doucet D; Kien P; Bonnemain B; Caillé JM
Invest Radiol; 1988 Sep; 23 Suppl 1():S271-4. PubMed ID: 3198361
[TBL] [Abstract][Full Text] [Related]
43. Contrast-enhanced MR imaging of tuberculous pachymeningitis cranialis hypertrophica: case report.
Callebaut J; Dormont D; Dubois B; Chiras J; Bories J
AJNR Am J Neuroradiol; 1990; 11(4):821-2. PubMed ID: 2114775
[No Abstract] [Full Text] [Related]
44. Use of the magnetic resonance contrast agent gadodiamide in the central nervous system. Results of a multicenter trial.
Sze G; Brant-Zawadzki M; McNamara MT; Haughton VM; Kumar AJ; Maravilla KR; Aisen AM; Dreisbach JN; Bradley WG; Weinreb JC
Invest Radiol; 1993 Mar; 28 Suppl 1():S49-55. PubMed ID: 8486504
[TBL] [Abstract][Full Text] [Related]
45. Gadopentetate dimeglumine: observations on the clinical research process.
Kieffer SA
Radiology; 1990 Jan; 174(1):7-8. PubMed ID: 2403685
[No Abstract] [Full Text] [Related]
46. Demonstration of the area postrema with contrast-enhanced MR.
Williams KD; Dean B; Drayer BP
AJNR Am J Neuroradiol; 1990; 11(4):733-4. PubMed ID: 2114759
[No Abstract] [Full Text] [Related]
47. Impact of gadolinium-based contrast agents on the growth of fish cells lines.
Parant M; Sohm B; Flayac J; Perrat E; Chuburu F; Cadiou C; Rosin C; Cossu-Leguille C
Ecotoxicol Environ Saf; 2019 Oct; 182():109385. PubMed ID: 31260918
[TBL] [Abstract][Full Text] [Related]
48. Magnetic resonance imaging contrast agents. Design and physicochemical properties of gadodiamide.
Chang CA
Invest Radiol; 1993 Mar; 28 Suppl 1():S21-7. PubMed ID: 8486500
[No Abstract] [Full Text] [Related]
49. Hepatic in vivo video microscopic study for evaluating experimental and approved magnetic resonance contrast agents.
Kruskal JB; Lunderquist A; Clouse ME
Invest Radiol; 1994 Jun; 29 Suppl 2():S83-6. PubMed ID: 7928279
[No Abstract] [Full Text] [Related]
50. Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent.
Weinmann HJ; Brasch RC; Press WR; Wesbey GE
AJR Am J Roentgenol; 1984 Mar; 142(3):619-24. PubMed ID: 6607655
[TBL] [Abstract][Full Text] [Related]
51. The relationship between thermodynamics and the toxicity of gadolinium complexes.
Cacheris WP; Quay SC; Rocklage SM
Magn Reson Imaging; 1990; 8(4):467-81. PubMed ID: 2118207
[TBL] [Abstract][Full Text] [Related]
52. Progressive multifocal leukoencephalopathy: contrast enhancement on CT scans and MR images.
Wheeler AL; Truwit CL; Kleinschmidt-DeMasters BK; Byrne WR; Hannon RN
AJR Am J Roentgenol; 1993 Nov; 161(5):1049-51. PubMed ID: 8273607
[No Abstract] [Full Text] [Related]
53. Safety of magnetic resonance imaging contrast agents.
Shellock FG; Kanal E
J Magn Reson Imaging; 1999 Sep; 10(3):477-84. PubMed ID: 10508312
[TBL] [Abstract][Full Text] [Related]
54. Fatal reaction to gadopentetate dimeglumine.
Jordan RM; Mintz RD
AJR Am J Roentgenol; 1995 Mar; 164(3):743-4. PubMed ID: 7863905
[No Abstract] [Full Text] [Related]
55. Routine use of gadopentetate dimeglumine in cranial MR imaging of patients with AIDS.
Elster AD
AJR Am J Roentgenol; 1993 Sep; 161(3):680-1. PubMed ID: 8352135
[No Abstract] [Full Text] [Related]
56. Intraosseous meningioma: CT and MR appearance.
Lee HY; Prager J; Hahn Y; Ramsey RG
J Comput Assist Tomogr; 1992; 16(6):1000-1. PubMed ID: 1430425
[No Abstract] [Full Text] [Related]
57. Gadolinium-enhanced MR imaging of the spleen: artifacts and potential pitfalls.
Ito K; Mitchell DG; Honjo K; Fujita T; Awaya H; Takano K; Koike S; Matsumoto T; Matsunaga N
AJR Am J Roentgenol; 1996 Nov; 167(5):1147-51. PubMed ID: 8911169
[No Abstract] [Full Text] [Related]
58. GdDTPA-enhanced magnetic resonance imaging of the aqueous flow in the rabbit eye.
Cheng HM; Kwong KK; Xiong J; Chang C
Magn Reson Med; 1991 Jan; 17(1):237-43. PubMed ID: 2067398
[TBL] [Abstract][Full Text] [Related]
59. Optimal use of MR contrast agents: how much is enough?
Maravilla KR
AJNR Am J Neuroradiol; 1991; 12(5):881-3. PubMed ID: 1950916
[No Abstract] [Full Text] [Related]
60. Renal capsular hemangioma: unusual MR findings.
Rueckforth J; Rhode D; Baba H; Adam G
J Comput Assist Tomogr; 1995; 19(5):817-8. PubMed ID: 7560334
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
